However, a drug belonging to the class of treatment known as the SGLT2 inhibitor did not show a statistically significant benefit for the prevention of heart attack or stroke, even in patients with diagnosed cardiovascular disease.
Diabetics have an increased risk of heart problems, which makes cardiovascular drugs have important attention from doctors and patients.
Stephen Viviott of Brigham and Boston Venom's Hospital, a senior researcher in this cynical study, said that these findings were important for creating a clear picture of SGLT2 drugs that were so far addressed to patients with diagnosed carcasses.
AstraZeneca hopes that new data will help Farkiga expand into a wider range of patients.
The main results of the Clinical Study Statement, conducted on a group of 17,000 patients, were first published in September, but details were uncovered at Saturday's Annual Meeting of the American Heart Association and published simultaneously at Nev England Journal of Medicine.
These results show that Farkiga reduces by 27% the risk of hospitalization due to a heart problem, as well as the risk of kidney disease.
While two smaller studies involving competing drugs SGLT2 focused on patients with diagnosed heart disease, Viviott said that the overall picture of the declared study showed that the primary benefit of widespread cardiac prevention was.
"When we analyze three studies, it is clear that the primary benefit of this class of cardiovascular drugs is the reduction of heart failure," said Viviott.
For decades, diabetics have been focused primarily on reducing blood glucose levels at certain levels. But the predisposition of diabetics to other issues, such as heart failure, where the five-year survival rate is only 50%, shows that a more holistic approach is needed, says Viviott.
"The message is that how we can reduce glucose levels can be as important as the relationship we are working with. We should choose drugs that improve the patient's lifespan and not just drugs that have the efficacy of lowering blood glucose levels," said the doctor.
Farkiga competes with competing SGLT2 drugs, including Jardiance, produced by Eli Lilli and Boehringer Ingelheim and Invokana Johnson & Johnson, who have already shown increased life expectancy in patients with diagnosed cardiac problems, the so-called. Secondary prevention.
Since AstraZeneca studies have also evaluated patients without a diagnosis of cardiovascular disease, this study opens a wider market that includes primary prevention.
In the Declare study, no increased risk of amputations, fractures, bladder cancer or gangrene has been identified in patients treated with Farkig, problems occasionally observed in patients treated with SGLT, but there has been an increase in genital infections.